Full-Time

PD Research Associate

Confirmed live in the last 24 hours

ProKidney

ProKidney

201-500 employees

Develops cell therapy for chronic kidney disease

No salary listed

Junior, Mid

Winston-Salem, NC, USA

Category
Bioinformatics
Biology Lab & Research
Biology & Biotech
Requirements
  • Bachelor's or Master's degree in Cell Biology, Biotechnology, Biochemical Engineering, or a related field.
  • 2 plus years of experience in cell therapy and/or biopharmaceutical process development.
  • Ability in execution and troubleshooting experiments, analyzing/reporting/presenting data.
  • Experience in aseptic techniques is essential.
  • Demonstrated ability to effectively work in cross-functional teams, meet deadlines, and prioritize multiple projects.
  • Strong problem-solving abilities, critical thinking, and the ability to collaborate with cross-functional teams.
  • Strong verbal and written communication skills, including technical writing.
  • Understanding of GMP, GLP, and regulatory requirements for the development of cell-based therapies.
  • Demonstrated troubleshooting and problem-solving skills.
  • Understanding of basic statistics and working knowledge of statistical software (e.g. JMP).
  • Must be comfortable handling human tissues.
Responsibilities
  • Design and execution of experiments to optimize and improve processes for cell therapy manufacturing, including but not limited to media preparation, cell expansion and harvest, and product formulation.
  • Analyze experimental data and present results in a clear and actionable manner to stakeholders.
  • Provide technical expertise in the development and implementation of new techniques and technologies.
  • Support troubleshooting and process improvement initiatives.
  • Work closely with cross-functional teams, including Quality Assurance, Regulatory Affairs, and Manufacturing, to ensure the successful transfer of process into GMP clinical and commercial manufacturing.
  • Support the characterization and validation of cell therapy processes, ensuring compliance with regulatory guidelines and internal standards.
  • Conduct process performance qualification (PPQ) studies and support clinical trial material production.
  • Ensure that all process development activities adhere to GMP and applicable regulatory standards.
  • Support regulatory filings and audits as needed.
  • Preparation and review of technical documentation, including process development reports, batch records, SOPs (Standard Operating Procedures), and change controls.
  • Assist to identify potential risks in process development and manufacturing and implement strategies for mitigation, ensuring the successful advancement of cell therapy programs.
Desired Qualifications
  • Experience with regulatory submissions and support for inspections is a plus.

ProKidney focuses on developing a cell therapy called rilparencel to treat Chronic Kidney Disease (CKD). This therapy aims to preserve kidney function in patients with advanced CKD, potentially delaying or eliminating the need for dialysis, which many patients currently rely on. ProKidney targets a significant healthcare issue, as over 35 million adults in the U.S. are affected by CKD, with many progressing to dialysis each year. The company is in the late stages of clinical trials for rilparencel, which has shown promise in preserving kidney function. Unlike competitors, ProKidney is dedicated to a specific and underserved segment of the healthcare market, aiming to fill a critical gap in CKD treatment. The goal is to provide a viable alternative to dialysis, improving the quality of life for millions of patients.

Company Size

201-500

Company Stage

IPO

Headquarters

Winston-Salem, North Carolina

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • ProKidney raised $140 million, boosting clinical trials and R&D for rilparencel.
  • The FDA's approval of similar therapies may ease rilparencel's regulatory pathway.
  • Growing personalized medicine trends favor ProKidney's cell therapy approach.

What critics are saying

  • ProKidney's canceled Greensboro expansion may harm its reputation and stakeholder trust.
  • Increased manufacturing expenses could strain financial resources, affecting development pace.
  • Reliance on public offerings for capital may indicate potential cash flow issues.

What makes ProKidney unique

  • ProKidney is pioneering rilparencel, a novel cell therapy for CKD.
  • Rilparencel aims to delay or eliminate the need for dialysis in CKD patients.
  • ProKidney targets an underserved CKD market, addressing a critical treatment gap.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

-1%

2 year growth

-1%
Stock Titan
Jan 7th, 2025
ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference

WINSTON-SALEM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) - ProKidney Corp. (Nasdaq: PROK) ("ProKidney"), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that ProKidney's CEO, Bruce Culleton, M.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference.

Rhino Times
Nov 25th, 2024
The Best Laid Plans Of Mice And ProKidney...

In June 2023, ProKidney announced that the company planned to invest $485 million in a Greensboro biomedical factory that would create roughly 330 jobs - with those jobs averaging just under $75,000 a year.

Business North Carolina
Nov 22nd, 2024
ProKidney buys Winston-Salem land after passing on Greensboro deal

ProKidney's purchasing the buildings from Breit SE Industrial Propco, also known as Blackstone Real Estate Income Trust.

WFMY News 2
Nov 19th, 2024
ProKidney no longer coming to Greensboro, Chamber of Commerce confirms

ProKidney had previously planned to expand operations into Greensboro.

Bizjournals
Oct 23rd, 2024
Power 50 Five to Watch: Bruce Culleton, ProKidney

Less than six months after joining the company, Dr. Bruce Culleton was appointed CEO of ProKidney, a regenerative medicine that made one of the largest manufacturing investments in Triad history.